期刊文献+

注射用多西他赛磺丁基-β-环糊精包合物的体外抗肿瘤作用

In vitro antitumor effect of the sulfobutyl-β-cyclodextrin inclusion of docetaxel for injection
下载PDF
导出
摘要 为了评价注射用多西他赛磺丁基-β-环糊精包合物(ML061)对各种体外培养肿瘤细胞的细胞毒性作用,本研究选取MDA-MB-435、MDA-MB-435s、NCI-H446、HO-8910、Bcap-37、KB、SMMC-7721、HT-29、SW480、LS-174t、SGC-7901、MCF-7、A549、NCI-H460等14个肿瘤细胞株,分别用不同质量浓度(200,20,2,0.2,0.02,0.002,0.000 2,0.000 02μg/mL)ML061处理肿瘤细胞72 h,用MTT法测定细胞活力,并计算药物对各肿瘤细胞的半数抑制浓度IC50。结果发现,ML061可抑制多种体外培养的肿瘤细胞株的活力,且这种抑制作用呈剂量依赖性。与阳性对照药市售多西他赛注射液奥名润相比,在选取的14个肿瘤细胞株中,ML061对Bcap-37、MDA-MB-435、MDA-MB-435s、NCI-H446和SW480的IC50小于0.1μg/mL。ML061对人卵巢癌Bcap-37、人结肠癌SW480、人小细胞肺癌NCI-H446、人乳腺癌MDA-MB-435及MDA-MB-435s等肿瘤细胞株的体外抑制作用较强。总之,ML061抑制多种体外培养的肿瘤细胞增殖,与阳性对照药奥名润相同,以Bcap-37、SW480、NCI-H446和MDA-MB-435s这4个细胞株较为敏感,而MDA-MB-435对ML061的敏感性高于奥名润。 To evaluate the in vitro cytotoxicity of the sulfobutyl-β-cyclodextrin inclusion of docetaxel for injection (ML061) on various tumor cell lines, 14 tumor cell lines including MDA-MB-435, MDA-MB-435s, NCI-H446, HO-8910, Bcap-37, KB, SMMC-7721, HT-29, SW480, LS-174t, SGC-7901, MCF-7, A549 and NCI-H460 were used for the treatment with ML061 at different concentrations (200, 20, 2, 0. 2, 0. 02, 0. 002, 0. 000 2, 0. 000 02 txg/mL) for 72 h, then the cell proliferation was evaluated by MTT method, and finally ICso was calculated. It was found that ML061 selectively inhibited the proliferation of a variety of tumor cell lines in vitro, with a certain in vitro killing effect on the 14 tumor cell lines in a dose-dependent trend. It was found that among the 14 tumor cell lines, the IC50 values of Bcap-37, MDA-MB-435, MDA-MB-435s, NCI-H446 and SW480 were less than 0. 1 μg,/mL( being sensitive to ML061). Compared with the positive control Aomingrun, ML061 had stronger in vitro inhibition effect on human ovarian cancer Bcap-37, human colon cancer SW480, human small cell lung cancer NCI-H446, human breast cancer MDA-MB-435 and MDA-MB-435s. In conclusion, ML061 inhibits the proliferation of a variety of tumor cell lines in vitro, of which Bcap-37, SW480, NCI-H446 and MDA-MB-435s cell lines are as sensitive as Aomingrun, but MDA-MB-435 is more sensitive to ML061 than Aomingrun.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2012年第4期376-378,共3页 Journal of China Pharmaceutical University
关键词 多西他赛 磺丁基-β-环糊精包合物(ML061) 抗肿瘤作用 docetaxel sulfobutyl-β-cyclodextrin inclusion (ML061) antitumor effect
  • 相关文献

参考文献5

二级参考文献19

  • 1张保宁.乳腺癌临床研究的回顾与展望[J].中华医学杂志,2005,85(1):7-8. 被引量:47
  • 2HOU Jian-quan,HE Jun,WEN Duan-gai,CHEN Zi-xing,ZENG Jian.Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder[J].Chinese Medical Journal,2006(13):1118-1120. 被引量:15
  • 3Valero V. Primary chemotherapy with docetaxel for the management of breast cancer[J]. Oncology (Huntingt), 2002, 16 (6 Suppl 6) :S35-S43.
  • 4Nabholtz J M,Reese D M,Lindsay M A,et al. Evidence for the use of chemotherapy in breast cancer[J]. Int J Clin Oncol,2002, 7(4) :254-264.
  • 5Remmelink M, Salmon I, Delville J P, et al. In vitro characterization of soft tissue tumor chemosensitivity [J]. Anticancer Res, 1997,17(3C) :2009-2017.
  • 6Cortes J E, Pazdur R. Docetaxel[J]. J Clin Oncol, 1995, 13 (10) :2643-2655.
  • 7Yon Hoff D D. The taxoids: same roots, different drugs[J].Semin Oncol, 1997, 24(Suppl 13) :S3-S13.
  • 8Ten Bokkel Huinink W W, Prove A M, Piccart M, et al. A phase Ⅱ trial with doctaxel (Docetaxel) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group[J]. Ann Oncol, 1994, 5(6):527-532.
  • 9SJOSTROM J,BIOMQVIST C,yon BOGUSLAWSKI K,et al.The predictive value of bcl-2,bax,bcl-xL,bag-1,fas,and fasL for chemotherapy response in advanced breast cancer[J].Clin Cancer Res,2002,8(3):811-816.
  • 10GREENLEE RT,HILL-HARMON MB,MURRAYT.Cancer statistics[J].CA Cancer J Clin,2001,51 (1):15-36.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部